reports
Coloplast annoncerer ændringer i ledelsesteamet
Coloplast annoncerer ændringer i ledelsesteamet Coloplast offentliggør i dag ændringer til ledelsesteamet (ELT). Ændringerne omhandler Coloplasts urologiforretning og virksomhedens globale funktion for People & Culture. Leder af People & Culture, Dorthe Rønnau, har besluttet at forlade Coloplast for at starte et nyt kapitel i sin karriere. Dorthe Rønnau har haft forskellige roller på tværs af Coloplast-koncernen i næsten tre årtier. ”Coloplast har haft stor glæde af Dorthes værdier, integritet og stærke lederevner i hendes roller i Global Operations, Atos og People & Culture, og den øvers...
Coloplast announces changes to Executive Leadership Team
Coloplast announces changes to Executive Leadership Team Today, Coloplast is announcing changes to the company’s Executive Leadership Team (ELT). The changes relate to the company’s Interventional Urology business as well as the global People & Culture function. Executive Vice President of People & Culture, Dorthe Rønnau, has decided to leave Coloplast to pursue the next chapter in her career. She has spent close to three decades in different roles across the Coloplast Group. “Dorthe’s values, integrity and strong leadership skills have benefitted the company across her roles in Global Op...
Coloplast A/S - Beslutninger på den ordinære Generalforsamling 2025
Coloplast A/S - Beslutninger på den ordinære Generalforsamling 2025 I dag, den 4. december 2025, afholdt Coloplast A/S sin ordinære generalforsamling, hvor følgende beslutninger blev vedtaget: Årsrapporten for regnskabsåret 2024/25 blev godkendt.Forslag om udbetaling af udbytte for året på 18,00 kr. pr. aktie à nominelt 1 kr. blev godkendt. I tillæg til de 5,00 kr. pr. aktie à nominelt 1 kr., der blev udbetalt i forbindelse med Coloplast A/S’ halvårsresultat, bliver det samlede udbytte for regnskabsåret 2024/25 således 23,00 kr. pr. aktie à nominelt 1 kr.Vederlagsrapporten for regnskabsåre...
Coloplast A/S - Decisions at the Annual General Meeting 2025
Coloplast A/S - Decisions at the Annual General Meeting 2025 Today, 4 December 2025, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted: The annual report for the financial year 2024/25 was approved.Distribution of year-end dividend of DKK 18.00 per share of nominally DKK 1 was approved. In addition to the interim dividend of DKK 5.00 per share of nominally DKK 1 paid out in connection with Coloplast A/S’ half- year result, this brings the total dividend paid for the financial year 2024/25 to DKK 23.00 per share of nominally DKK 1.The remuneratio...
Coloplast A/S - Indkaldelse til ordinær generalforsamling 2025
Coloplast A/S - Indkaldelse til ordinær generalforsamling 2025 Indkaldelse til ordinær generalforsamling 2025 Den ordinære generalforsamling i Coloplast A/S afholdes torsdag den 4. december 2025 kl. 15:30 på Coloplast A/S’ adresse, Holtedam 3 (Aage Louis-Hansen Auditorium), Humlebæk, Danmark. Indkaldelsen til den ordinære generalforsamling er vedlagt. For yderligere information, kontakt venligst Investorer og analytikereAnders Lonning-SkovgaardExecutive Vice President, CFOTlf. 4911 1111 Kristine Husted MunkSr. Director, Investor RelationsTlf. 4911 1800 / 4911 3266Email: Simo...
Coloplast A/S - Notice of Annual General Meeting 2025
Coloplast A/S - Notice of Annual General Meeting 2025 Notice of Annual General Meeting 2025 The Annual General Meeting of Coloplast A/S will be held on Thursday, 4 December 2025 at 3:30 pm CET at the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the Aage Louis-Hansen Auditorium), Humlebæk, Denmark. The notice of the Annual General Meeting is enclosed. For further information, please contact Investors and analystsAnders Lonning-SkovgaardExecutive Vice President, CFOTel. Kristine Husted MunkSr. Director, Investor RelationsTel. / Email: Simone Dyrby HelvindSr. Manager, Inve...
- Emira Sagaama
- Louis Boujard
- CFA
- Philippe Ourpatian
DHLN DHL GROUP
CON CONTINENTAL AKTIENGESELLSCHAFT
LRC LEGRAND
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
VIE VEOLIA ENVIRONNEMENT SA
EDEN EDENRED SA
ENGI ENGIE SA.
EDP EDP-ENERGIAS DE PORTUGAL SA
BT.A BT GROUP PLC
MT ARCELORMITTAL SA
DGE DIAGEO PLC
RNO RENAULT SA
G1A GEA GROUP AG
KPN ROYAL KPN NV
GFC GECINA SA
DAI DAIMLER AG
EBS ERSTE GROUP BANK AG
ADEN ADECCO GROUP AG
SCMN SWISSCOM AG
MMK MAYR-MELNHOF KARTON AG
RHM RHEINMETALL AG
CDR CD PROJEKT S.A.
PKO PKO BANK POLSKI S.A.
TEP TELEPERFORMANCE SE
RF EURAZEO SA
ZAL ZALANDO SE
GEBN GEBERIT AG
ORSTED ORSTED
HEI HEIDELBERGCEMENT AG
VER VERBUND AG CLASS A
VOW3 VOLKSWAGEN AG PREF
HEN3 HENKEL AG & CO. KGAA PREF
CRG CRH PLC
FCC FOMENTO DE CONSTRUCCIONES Y CONTRATAS S.A.
RAA RATIONAL AG
EDW EDP RENOVAVEIS SA
TIT TELECOM ITALIA S.P.A.
COLO B COLOPLAST A/S CLASS B
INX IMCD N.V.
LDO LEONARDO SPA
AZN ASTRAZENECA PLC
NEXI NEXI S.P.A.
STLA STELLANTIS N.V.
VWS VESTAS WIND SYSTEMS
CTPNV CTP NV
NOVO B NOVO NORDISK A/S
ARM ARM HOLDINGS PLC
SYENS SYENSQO
UN0 UNIPER SE
AENA AENA S.M.E. SA
- Emira Sagaama
- Louis Boujard
- CFA
- Philippe Ourpatian
DHLN DHL GROUP
CON CONTINENTAL AKTIENGESELLSCHAFT
LRC LEGRAND
VIE VEOLIA ENVIRONNEMENT SA
EDEN EDENRED SA
ENGI ENGIE SA.
EDP EDP-ENERGIAS DE PORTUGAL SA
BT.A BT GROUP PLC
MT ARCELORMITTAL SA
DGE DIAGEO PLC
G1A GEA GROUP AG
KPN ROYAL KPN NV
GFC GECINA SA
EBS ERSTE GROUP BANK AG
ADEN ADECCO GROUP AG
SCMN SWISSCOM AG
MMK MAYR-MELNHOF KARTON AG
RHM RHEINMETALL AG
CDR CD PROJEKT S.A.
PKO PKO BANK POLSKI S.A.
TEP TELEPERFORMANCE SE
RF EURAZEO SA
ZAL ZALANDO SE
GEBN GEBERIT AG
ORSTED ORSTED
HEI HEIDELBERGCEMENT AG
VER VERBUND AG CLASS A
HEN3 HENKEL AG & CO. KGAA PREF
CRG CRH PLC
FCC FOMENTO DE CONSTRUCCIONES Y CONTRATAS S.A.
RAA RATIONAL AG
EDW EDP RENOVAVEIS SA
TIT TELECOM ITALIA S.P.A.
COLO B COLOPLAST A/S CLASS B
INX IMCD N.V.
LDO LEONARDO SPA
AZN ASTRAZENECA PLC
NEXI NEXI S.P.A.
VWS VESTAS WIND SYSTEMS
CTPNV CTP NV
NOVO B NOVO NORDISK A/S
ARM ARM HOLDINGS PLC
SYENS SYENSQO
UN0 UNIPER SE
AENA AENA S.M.E. SA
- Oliver Metzger
- ABGSC Healthcare Research
- Morten Larsen
- Oliver Metzger
- Thomas Zlowodzki
- Wim Gille
FME FRESENIUS MEDICAL CARE AG
EDEN EDENRED SA
DBK DEUTSCHE BANK AG
ULVR UNILEVER PLC
MMK MAYR-MELNHOF KARTON AG
PHIA KONINKLIJKE PHILIPS N.V.
GEBN GEBERIT AG
NXT NEXT PLC
RY4C RYANAIR HOLDINGS PLC
NEM NEMETSCHEK SE
ARCAD ARCADIS NV
EVK EVONIK INDUSTRIES AG
COLO B COLOPLAST A/S CLASS B
SNP PETROM S.A.
BP. BP P.L.C.
BIM BIOMERIEUX SA
TEF TELEFONICA SA
BNTX BIONTECH SE
AMRZ AMRIZE AG
AAL ANGLO AMERICAN PLC
- Oliver Metzger
- Thomas Zlowodzki
- Wim Gille
FME FRESENIUS MEDICAL CARE AG
EDEN EDENRED SA
DBK DEUTSCHE BANK AG
ULVR UNILEVER PLC
MMK MAYR-MELNHOF KARTON AG
PHIA KONINKLIJKE PHILIPS N.V.
GEBN GEBERIT AG
NXT NEXT PLC
RY4C RYANAIR HOLDINGS PLC
NEM NEMETSCHEK SE
ARCAD ARCADIS NV
EVK EVONIK INDUSTRIES AG
COLO B COLOPLAST A/S CLASS B
SNP PETROM S.A.
BP. BP P.L.C.
BIM BIOMERIEUX SA
TEF TELEFONICA SA
BNTX BIONTECH SE
AMRZ AMRIZE AG
AAL ANGLO AMERICAN PLC
- Oliver Metzger
- ABGSC Healthcare Research
- Morten Larsen
Coloplast A/S - Annual Report 2024/25 & Remuneration Report 2024/25
Coloplast A/S - Annual Report 2024/25 & Remuneration Report 2024/25 Coloplast A/S - Annual Report 2024/25 & Remuneration Report 2024/25 FY 2024/25 organic growth of 7% and EBIT margin1 of 28%. Reported revenue in DKK grew 3% to DKK 27,874 million.• Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice & Respiratory Care 9%, Wound & Tissue Repair 8% and Interventional Urology 2%.• EBIT1,2 was DKK 7,670 million, a 5% increase from last year. The EBIT margin1,2 was 28%, against 27% last year.• Adjusted3 net profit before special items was DKK 5,148 million, a DKK 12...
Coloplast A/S - Årsregnskabsmeddelelse 2024/25
Coloplast A/S - Årsregnskabsmeddelelse 2024/25 2024/25Årsregnskabsmeddelelse 1. oktober 2024 - 30. september 2025 Organisk vækst på 7% og en overskudsgrad1 på 28% i 4. kvartal. Den rapporterede omsætning i danske kroner steg 0%, negativt påvirket af valutaudviklingen samt frasalget af hudplejeforretningen.• Organisk vækst pr. område: Stomi 7%, Kontinens 9%, Stemme og Respiratorisk Pleje 9%, Wound & Tissue Repair 5% og Urologi 2%.• Væksten i Stomi var bredt funderet, med et godt bidrag fra nylige produktlanceringer og drevet af Europa og Øvrige markeder ex. Kina. Salget i Kina fa...
Coloplast A/S - Full-Year Financial Results 2024/25
Coloplast A/S - Full-Year Financial Results 2024/25 2024/25Full year financial results 1 October 2024 - 30 September 2025 Coloplast delivered Q4 organic growth of 7% and an EBIT margin1 of 28%. Reported revenue in DKK grew 0% with negative impact from currencies and the Skin Care divestment.• Organic growth rates by business area: Ostomy Care 7%, Continence Care 9%, Voice & Respiratory Care 9%, Wound & Tissue Repair 5% and Interventional Urology 2%.• Growth in Ostomy Care was broad based with good contribution from recent product launches and led by Europe and Emerging Markets ex. China. ...
Coloplast A/S - FY 2024/25 Earnings Release - Invitation for conferenc...
Coloplast A/S - FY 2024/25 Earnings Release - Invitation for conference call on 4 Nov 2025 at 11.00 CET Tuesday, 4 November 2025 at 11:00 - 12:00am CETIn connection with the publication of Coloplast’s interim financial results for FY 2024/25, to be released same day around 07.00am CET, Coloplast will host a conference call to present the financial results and answer questions from investors and financial analysts. A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.The webcast of the conference call will be available during and after the ...
- ABGSC Healthcare Research
- Morten Larsen
Coloplast interim CEO Lars Rasmussen udtræder af bestyrelsen ved den k...
Coloplast interim CEO Lars Rasmussen udtræder af bestyrelsen ved den kommende ordinære generalforsamling Selskabsmeddelelse nr. 09/2025Intern viden Coloplast interim CEO Lars Rasmussen udtræder af bestyrelsen ved den kommende ordinære generalforsamling Interim CEO Lars Rasmussen har i dag informeret Coloplasts bestyrelse om, at han ikke genopstiller som bestyrelsesmedlem ved den kommende ordinære generalforsamling den 4. december 2025. ”På vegne af bestyrelsen vil jeg gerne takke Lars for hans mangeårige engagement i Coloplast. Gennem næsten fire årtiers virke – herunder 10 år som CEO og...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.